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Objectives:  This  study  is  aimed  at  analyzing  the  impact  of  the  main  factors  contributing  to
short and  long-term  mortality  in  patients  at  final  stages  of  heart  failure  (HF).
Setting:  Patients  attended  at  any  of  the  279  primary  health  care  centers  belonging  to  the
Institut Català  de  la  Salut,  in  Catalonia  (Spain).
Participants:  Patients  with  Advanced  HF.
Design:  Multicenter  cohort  study  including  1148  HF  patients  followed  for  one-year  after  reach-
ing New  York  Heart  Association  (NYHA)  IV.
Main measurements:  The  primary  outcome  was  all-cause  mortality.  Multivariate  logistic  regres-
sion models  were  performed  to  assess  the  outcomes  at  1,  3,  6,  and  12  months.
Results: Mean  age  of  patients  was  82  (SD  9)  years  and  women  represented  61.7%.  A  total  of  135
(11.8%) and  397  (34.6%)  patients  died  three  months  and  one  year  after  inclusion,  respectively.
Male gender,  age,  and  decreased  body  mass  index  were  associated  with  higher  mortality  at
three, six  and  twelve  months.  In  addition,  low  systolic  blood  pressure  levels,  severe  reduction
in glomerular  filtration,  malignancy,  and  higher  doses  of  loop  diuretics  were  related  to  higher
mortality from  6  to  12  months.
actor  over  the  whole  period  was  presenting  a  body  mass  index  lower
s  OR  3.06,  95%  CI:  1.58--5.92;  six  months  OR  4.42,  95%  CI:  2.08--9.38;
%  CI:  1.76--7.69).The  most  important  risk  f
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Conclusions:  We  may  conclude  that  male,  age,  and  decreased  body  mass  index  determined
higher short-term  mortality  in  NYHA  IV.  In  addition,  low  systolic  blood  pressure,  reduced
glomerular  filtration,  malignancy,  and  higher  doses  of  loop  diuretics  contribute  to  increasing
the risk  of  mortality  at  medium  and  long-term.  Such  variables  are  easily  measurable  and  can
help to  decide  the  best  way  to  face  the  most  advances  stages  of  the  disease.
© 2019  The  Authors.  Published  by  Elsevier  España,  S.L.U.  This  is  an  open  access  article  under




Fin  de  vida;
Epidemiología;
Factores  pronósticos
Mortalidad  a  corto  plazo  en  los  pacientes  con  insuficiencia  cardiaca  en  estadios
finales
Resumen
Objetivos:  Analizar  los  factores  que  contribuyen  a  la  mortalidad  de  pacientes  en  las  etapas
finales de  la  insuficiencia  cardiaca  (IC).
Ámbito:  Centros  de  atención  primaria  del  Institut  Català  de  la  Salut,  Cataluña,  España.
Participantes:  Pacientes  con  IC  avanzada.
Diseño: Estudio  de  cohortes  multicéntrico.  Incluyó  1.148  pacientes  de  IC  seguidos  durante  un
año tras  el  registro  de  estadio  funcional  NYHA  IV.
Mediciones  principales:  El  resultado  principal  fue  la  mortalidad  por  todas  las  causas.  Se
realizaron  modelos  de  regresión  logística  multivariada  (1,  3,  6  y  12  meses).
Resultados:  Edad  media  82  años  (DE  9),  las  mujeres  representaron  el  61,7%.  Un  total  de  135
(11,8%) y  397  (34,6%)  pacientes  murieron  3  meses  y  un  año  después  de  su  inclusión.  El  sexo
masculino,  la  edad  y  el  índice  de  masa  corporal  (IMC)  <  20  kg/m2 se  asociaron  con  una  mayor
mortalidad  a  los  3,  6  y  12  meses.  Bajos  niveles  de  presión  arterial  sistólica,  reducción  severa
en el  filtrado  glomerular,  malignidad  y  dosis  altas  de  diuréticos  fueron  relacionadas  con  una
mortalidad más  alta  de  6  a  12  meses.
El factor  de  riesgo  más  importante  fue  un  IMC  <  20  kg/m2 (3  meses  OR:  3,06;  IC  95%:  1,58-5,92;
6 meses  OR:  4,42;  IC  95%:  2,08-9,38  y  12  meses  OR:  3,68;  IC  95%:  1,76-7,69).
Conclusiones:  Los  varones,  la  edad  avanzada  y  un  IMC  disminuido  determinaron  una  mortalidad
a corto  plazo  más  alta  en  pacientes  NYHA  IV.  La  baja  presión  arterial  sistólica,  la  reducción
del filtrado  glomerular,  la  malignidad  y  las  dosis  altas  de  diuréticos  aumentan  el  riesgo  de
mortalidad  a  medio  y  largo  plazo.  Estas  variables  son  fáciles  de  obtener,  y  pueden  ayudar  a
decidir las  mejores  estrategias  para  afrontar  los  estadios  más  avanzados  de  la  enfermedad.
© 2019  Los  Autores.  Publicado  por  Elsevier  España,  S.L.U.  Este  es  un  art́ıculo  Open  Access  bajo
































eart  failure  (HF)  affects  more  than  10%  of  those  aged  over
0  years,  and  in  individuals  over  65  it  is  the  major  reason  for
ospitalization  and  the  third  leading  cause  of  death.1,2 The
linical  course  of  HF  is  progressive  and  eventually  results  in
dvanced  stages  leading  to  transplantation  or  death.3
Although  HF  symptoms,  burden,  and  mortality  are  similar
o  the  most  prevalent  cancers,2,3 little  has  been  published
egarding  the  final  stages  of  advanced  HF  patients  man-
ged  mainly  in  primary  care  setting.  Due  to  their  particular
haracteristics,  such  as  old  age  and  comorbidities,  most
f  these  patients  are  not  candidates  for  transplantation  or
mplantable  devices,  and  palliative  measures  are  commonly
eeded.  Accurate  knowledge  regarding  the  factors  related
o  a  curtailed  life  expectancy  would  guide  health  profession-
ls,  together  with  patients  and  families,  in  deciding  where
nd  when  to  provide  treatment,  as  well  as  how  to  carry
ut  the  appropriate  palliative  and  comfort  measures.4,5





uctuate  rapidly  as  the  patient’s  condition  becomes  increas-
ngly  deteriorated.
There  are  no  specifically  designed  models  to  describe
he  prognosis  of  terminal  HF  patients,  consequently,  some
f  them  underestimate  the  risk  of  dying,  and  often  include
 number  of  variables  not  easily  obtained  in  general  prac-
ice.  Such  models  do  not  thus  properly  represent  most  of
he  advanced  HF  population  attended  in  primary  care.6--9
The  aim  of  our  study  was  to  identify  variables  accessible
n  general  practice  which  can  determine  the  impact  of  the
ain  prognostic  factors  contributing  to  mortality  at  short
nd  long-term  in  patients  at  final  stages  of  HF.
ethods
e  carried  out  a  multicenter  cohort  study  based  on  infor-
ation  from  the  SIDIAP  database  (Information  System  for
he  Development  of  Research  in  Primary  Care  System).  This
atabase  contains  the  daily  clinical  activities  registered


































Short-term  mortality  in  end-stage  heart  failure  patients  
information  from  over  five  million  patients’  electronic
records  (EMR).10
Patient  population
Study  population  were  patients  older  than  44  years  regis-
tered  as  having  HF  (International  Classification  Diseases  10th
version:  I.50)  at  stage  IV  of  the  New  York  Heart  Associa-
tion  (NYHA)  on  31st  December,  2013.  To  be  included  in  the
analysis,  patients  must  have  been  attended  at  least  once
during  the  study  period  at  any  of  the  279  primary  health
care  centers.
Patients  were  included  when  they  were  registered  as  hav-
ing  NYHA  IV  in  the  patient’s  EMR  in  the  period  between  1st
January,  2010,  and  31st  December,  2013.  All  patients  had  a
follow-up  for  at  least  one  year  or  until  they  died  during  this
period.
Variables  included  in  the  analysis  were:  socio  demo-
graphic  (gender,  age),  cardiovascular  risk  factors  and
comorbidities  (hypertension,  diabetes,  coronary  heart  dis-
ease,  stroke,  and  atrial  fibrillation),  other  comorbidities
(chronic  renal  disease,  chronic  pulmonary  disease,  and  can-
cer),  laboratory  tests  (sodium,  potassium,  creatinine,  and
hemoglobin),  considering  anemia  an  hemoglobin  <13  g/dL
in  men  and  12  g/dL  in  women,  and  Hyponatremia  if
Na  <  140  mmol/L,  daily  living  activities  assessment,  and
treatment  related  to  HF  (beta-blockers  (BB),  angiotensin-
converting  enzyme  inhibitors  (ACEi),  angiotensin  receptor
blockers  (ARB),  mineral  corticoid  antagonists  (MRA),  and
loop  diuretics).  In  order  to  perform  the  analysis  ACEi  and
ARB  were  grouped  together.
Blood  pressure,  body  mass  index,  and  heart  rate  were
categorized  as  hypotension  (systolic  blood  pressure  (SBP)
<90  mmHg),  low  body  mass  index  (<20  kg/m2),  and  high  heart
rate  (>100  b/min),  respectively.
The  main  outcome  was  all-cause  mortality  (at  one,  three,
six,  and  twelve  months)  after  NHYA  IV  registration  in  EMR.
Statistical  analysis
Continuous  variables  were  expressed  as  mean  and  stan-
dard  deviation  while  categorical  variables  were  described  as
total  number  and  percentages.  Univariate  analysis  between
patients’  characteristics  (socio-demographic,  comorbidi-
ties,  clinical  and  analytic  information,  daily  living  activities,
and  medical  treatment  related  to  HF)  and  mortality  outcome
were  performed  using  student’s  t  test  and  chi-square  test  or
Fisher’s  exact  test  as  appropriate.  The  unadjusted  odds  ratio
was  also  computed.  Multivariate  logistic  regression  analyses
were  performed  to  analyze  the  association  of  mortality  (at
one,  three,  six,  and  twelve  months  after  reaching  the  NYHA
IV  stage  of  HF)  and  the  patients’  characteristics.  A  multi-
ple  imputation  with  the  predictive  mean  matching  method
was  carried  out  to  deal  with  the  missing  values  of  the  varia-
bles  considered  in  the  multivariate  model.  To  generate  the
imputations  all  the  patients’  information  was  taken  into
account.  Twenty  imputations  were  generated  and  the  values
combined  using  Rubin’s  rules.11 The  significance  level  was
fixed  at  0.05.  Analysis  was  performed  using  R  software  for






ienna,  Austria).  The  multiple  imputations  were  carried  out
ith  the  aregImpute  function  in  the  Hmisc  package.
thics
ll  ethical  aspects  were  taken  into  consideration.  The  study
rotocol  was  approved  by  the  local  Clinical  Ethic  Committee
reference  number  P13/052).
esults
escriptive  analysis
aseline  characteristics  of  patients  are  shown  in  Table  1.
mong  the  1148  patients,  women  represented  61.7%,  mean
ge  was  82  (SD  9)  years,  and  82.8%  were  more  than  75
ears  old.  The  most  prevalent  cardiovascular  comorbidi-
ies  at  baseline  were  hypertension  (79.2%),  atrial  fibrillation
46.7%),  and  diabetes  (42.2%).  One  third  of  the  patients  had
 history  of  coronary  heart  disease  and  14.3%  had  had  a
revious  stroke.  Among  the  non-cardiovascular  comorbidi-
ies,  the  most  frequent  was  chronic  kidney  disease  (34.1%).
he  most  commonly  prescribed  medication  were  ACEi/ARB
66.6%)  followed  by  BB  (45%),  and  MRA  (26.5%).
Women  were  more  commonly  older,  hypertensive,  and
ad  atrial  fibrillation  whilst  men  suffered  more  frequently
rom  coronary  heart  disease,  chronic  obstructive  pulmonary
isease,  and  cancer.  Mineral  corticoid  receptors  antagonist
ere  more  frequently  prescribed  in  men  and  no  differences
ere  found  regarding  the  rest  of  the  medication.
Fig.  1  depicts  the  evolution  in  mortality  during  the  first
ear  after  reaching  NYHA  IV.  It  can  be  observed  that  the
lope  of  the  curve  was  higher  in  the  first  six  months.
nivariate  analysis
uring  the  first  year  mortality  constantly  increased  (4.2%  at
 month,  11.8%  at  3  months,  22.6%  at  6  months,  and  34.6%
t  12  months,  respectively).
Cardiovascular  comorbidity  did  not  significantly  affect
ortality  at  any  time  during  the  first  year  after  reaching
YHA  IV.  Only  age  and  hyponatremia  were  related  to  higher
ortality  at  very  early  stages  (one  month).  From  the  sixth
onth  onwards,  male  gender,  age,  high  dependency  on  daily
ctivities,  cancer,  hyponatremia,  chronic  renal  disease,  low
BP,  and  decreased  body  mass  index  were  associated  with  a
igher  risk  of  mortality.  Reduced  levels  of  hemoglobin  and
480  J.M.  Verdú-Rotellar  et  al.
Table  1  Baseline  characteristics  of  heart  failure  patients.
Total  N  =  1148  Women  N  =  708  Men  N  =  440  p  Value
Age  (%) <0.001
<50  3  (0.26)  2  (0.28)  1  (0.23)
50 to  74  195  (17.0)  90  (12.7)  105  (23.9)
≥75 950  (82.8)  616  (87.0)  334  (75.9)
Age (years)  81.6  (8.87)  83.1  (8.42)  79.2  (9.04)  <0.001
Smoking habit  (%)
Non-smoker  838  (74.2)  648  (93.4)  190  (43.7)  <0.001
Active smoker  41  (3.63)  8  (1.15)  33  (7.59)
Former smoker 250  (22.1)  38  (5.48)  212  (48.7)
Barthel <20  (1  to  100)  (%) 90  (12.3) 67  (14.5) 23  (8.46) 0.022
Comorbidity
Hypertension  (%)  909  (79.2)  594  (83.9)  315  (71.6)  <0.001
Diabetes (%)  485  (42.2)  286  (40.4)  199  (45.2)  0.121
Coronary heart  disease  (%)  375  (32.7)  184  (26.0)  191  (43.4)  <0.001
Stroke (%)  164  (14.3)  91  (12.9)  73  (16.6)  0.094
Atrial fibrillation  (%)  536  (46.7)  356  (50.3)  180  (40.9)  0.002
Chronic renal  disease  (%)  391  (34.1)  253  (35.7)  138  (31.4)  0.146
Chronic pulmonary  disease  (%)  378  (32.9)  145  (20.5)  233  (53.0)  <0.001
Cancer (%)  216  (18.8)  114  (16.1)  102  (23.2)  0.004
Clinical variables
Systolic  blood  pressure  ≤90  mmHg  (%)  37  (3.46)  18  (2.71)  19  (4.67)  0.127
Body mass  index  <20  kg/m2 (%)  36  (4.21)  19  (3.75)  17  (4.87)  0.532
Heart rate  >  100  min--1 (%)  55  (5.41)  33  (5.25)  22  (5.67)  0.887
Charlson ≥  6  (%)  155  (13.5)  77  (10.9)  78  (17.7)  0.001
Glomerular  filtration  <30  mL/min  (%)  97  (11.9)  63  (12.4)  34  (11.1)  0.675
Anemia (<13  g/dL  in  men  and  <12  g/dL  in  women)  421  (53.8)  245  (49.9)  176  (60.3)  0.006
Hyponatremia  (<140  mmol/L)  234  (30.7)  143  (29.7)  91  (32.4)  0.493
Laboratory tests
Sodium  (mg/dL)  141  (3.62)  141  (3.61)  141  (3.63)  0.337
Potassium (mg/dL)  4.53  (0.55)  4.50  (0.53)  4.57  (0.58)  0.113
Hemoglobin  (g/dL)  12.2  (1.80)  12.0  (1.68)  12.5  (1.94)  <0.001
Creatinine (mg/dL)  1.24  (0.60)  1.15  (0.51)  1.39  (0.71)  <0.001
Medication
ACEi/ARB *(%)  758  (66.0)  478  (67.5)  280  (63.6)  0.199
Beta blockers  (%)  517  (45.0)  325  (45.9)  192  (43.6)  0.490
MRAs† (%)  304  (26.5)  162  (22.9)  142  (32.3)  0.001
Doses of  loop  diuretics  (mg)  55.7  (44.3)  54.5  (42.5)  57.8  (47.1)  0.243



















ACEi/ARB indicates angiotensin converting enzyme inhibitor/A
† MRAs, Mineralocorticoid Receptor Antagonists.
aised  loop  diuretic  doses  were  related  to  mortality  at  six
nd  twelve  months  (Table  2).
ultivariate  analysis
ome  variables  had  missing  values,  especially  the  Barthel
ndex  (36%),  hemoglobin  levels  (32%),  and  glomerular  filtra-
ion  rate  (29%).  We  present  the  final  adjusted  multivariate
odels  after  performing  multiple  missing  imputation.
In  the  first  month  the  prescription  of  ACE  inhibitors  or  ARB
esulted  in  a  protective  effect  (OR  0.46  95%  CI  0.26--0.84).
his  effect  remained  along  the  first  year  but  was  not  statis-




ensin II receptor blockers.
Three  months  after  reaching  NYHA  IV  the  main  factors
elated  to  higher  mortality  were  male  gender,  increased  age,
nd  reduced  body  mass  index.  Six  months  after  reaching
YHA  IV  the  effect  of  the  former  variables  remained  signif-
cant  and  other  variables  presented  statistical  significance
n  the  multivariate  model,  such  as  reduced  glomerular  fil-
ration,  low  SBP,  cancer,  and  the  loop  diuretic  doses  used  to
anage  HF.iscussion
ur  study,  based  on  real  world  data  from  clinical  records,
dds  information  to  previous  evidence  about  HF  prognosis.























Figure  1  Evolution  in  the  cumulate  incidence  of  mortality  d
(N =  1148).
It  describes  the  evolution  and  impact  short-term,  and  at  one
year,  of  the  main  prognostic  factors  after  reaching  NYHA  IV,
and  is  specifically  focused  on  stable,  advanced  HF  patients
managed  in  primary  care.  At  three  months,  only  age,  male
gender,  and  reduced  body  mass  index  resulted  in  higher
mortality.  At  six  and  12  months  these  factors  were  still
related  to  higher  mortality  with  the  addition  of  decreased
glomerular  filtration,  low  SBP,  cancer,  and  higher  doses  of
furosemide.
A  number  of  scores  have  been  developed  to  predict  the
prognosis  of  HF  patients,  in  most  of  them,  however,  survival
was  analyzed  at  long-term  (one  year  or  more),  partici-
pants  were  recruited  in  hospitals,  the  proportion  of  NYHA
IV  was  lower  than  10%,  and  many  findings  were  based  on
variables  generally  complicated  to  obtain  in  non-hospital
settings.12--15 With  respect  to  mortality,  the  PRAISE  study
was  conducted  in  patients  with  NYHA  IIIb  and  IV  and  showed
an  annual  rate  of  11%.  The  CHARM  study  included  a  sample
of  173  patients  with  NYHA  IV  and  observed  a  figure  of  29%,
which  was  closer  to  our  findings.16,17 Ambardekaer  et  al.  also
reported  a  high  rate  of  mortality  after  a  16-month  follow-up
in  a  cohort  of  ambulatory  advanced  HF  patients  who  were
not  eligible  for  transplantation/left  ventricular  assisted
18device. Currently,  morbidity  and  mortality  for  individuals
with  advanced  HF  continues  to  be  elevated  and  comorbid-






g  the  first  year  after  reaching  New  York  Heart  Association  IV
omparative  analysis  of  mortality  determinants
egarding  gender,  it  has  already  been  argued  that  women
resent  higher  comorbidity  (with  the  exception  of  coro-
ary  heart  disease  such  as  HF)  and  symptom  severity  than
en,  but  better  survival.  It  is  plausible  to  think  that
his  could  have  influenced  prognosis,  nevertheless,  it  does
ot  completely  explain  differences  in  mortality  between
enders.20
Patients  with  SBP  levels  lower  than  90  mmHg  had  a  more
han  two-fold  risk  of  death  in  comparison  with  the  oth-
rs,  as  previously  observed  by  Vidán  et  al.  They  justified
his  result  by  the  fact  that  patients  with  higher  SBP  on
ospital  admission  were  younger,  healthier,  and  received
ore  aggressive  treatment.  In  addition,  the  pathophysiology
ight  differ  in  patients  with  HF  and  higher  blood  pressure.21
imilar  results  were  also  reported  in  advanced  chronic  sys-
olic  HF  patients  although  the  SBP  cut-off  was  120  mm  Hg.
he  authors  hypothesized  that  their  findings  could  be  related
o  a greater  incidence  of  ischemic  heart  disease  in  patients
ith  lower  blood  pressure.22 In  our  study  such  an  effect
n  mortality  was  found  to  be  independent  of  age,  treat-
ent,  and  comorbidity.  The  latest  version  of  the  Europeanociety  of  Cardiology  Clinical  Practice  Guidelines  includes
ypotension  as  a factor  of  poor  ischemic  cardiomyopathy
rognosis  and  proposes  these  patients  be  candidates  for  the








Table  2  Risk  factors  related  to  mortality  at  1,  3,  6,  and  12  months.
N  Mortality  1  month  Mortality  3  months  Mortality  6  months  Mortality  1  year
N  (%)  p  Value  N  (%)  p  Value  N  (%)  p  Value  N  (%)  p  Value
Sex  0.738  0.043  0.055  0.002
Women 708  28  (3.95)  72  (10.2)  146  (20.6)  220  (31.1)
Men 440  20  (4.55)  63  (14.3)  113  (25.7)  177  (40.2)
Age (1  year)  1148  84.3  (8.95)  0.039  84.8  (8.19)  <0.001  84.3  (8.25)  <0.001  83.7  (8.35)  <0.001
Age (two  cathegories)
45--74  years  198  6  (3.0) 0.048 13  (6.5) 0.018 26  (13.1) 0.006 47  (23.7) 0.001
≥75 years  950  42  (4.4)  122  (12.8)  233  (24.5)  350  (36.8)
Smoking habit  0.837  0.156  0.469  0.935
Non-smoker 838  35  (4.2)  101  (12.1)  194  (23.2)  292  (34.8)
Active smoker  41  1  (2.4)  1  (2.44)  7  (17.1)  14  (34.1)
Former smoker  250  12  (4.8)  31  (12.4)  51  (20.4)  84  (33.6)
Comorbidity (%)
Barthel  index  0.070  0.194  0.012  0.032
≥20 644  28  (4.3)  85  (13.2)  159  (24.7)  242  (37.6)
<20 90  8  (8.9)  17  (18.9)  34  (37.8)  45  (50.0)
Hypertension 0.584  0.589  0.426  0.176
No 239  12  (5.0)  31  (13.0)  59  (24.7)  92  (38.5)
Yes 909  36  (3.9)  104  (11.4)  200  (22.0)  305  (33.6)
Diabetes 0.259  0.032  0.323  0.247
No 663  32  (4.8)  90  (13.6)  157  (23.7)  239  (36.0)
Yes 485  16  (3.3)  45  (9.28)  102  (21.0)  158  (32.6)
Coronary heart  disease  0.955  0.755  0.640  0.876
No 773  33  (4.3)  93  (12.0)  178  (23.0)  269  (34.8)
Yes 375  15  (4.0)  42  (11.2)  81  (21.6)  128  (34.1)
Stroke 0.125  0.751  0.920  1.000
No 984  37  (3.7)  114  (11.6)  221  (22.5)  340  (34.6)
Yes 164  11  (6.7)  21  (12.8)  38  (23.2)  57  (34.8)
Atrial fibrillation  0.748  0.787  0.517  0.607
No 612  24  (3.9)  70  (11.4)  133  (21.7)  207  (33.8)
Yes 536  24  (4.5)  65  (12.1)  126  (23.5)  190  (35.4)
Chronic renal  disease  0.720  0.042  0.010  0.008
No 757  30  (3.9)  78  (10.3)  153  (20.2)  241  (31.8)











Table  2  (Continued)
N  Mortality  1  month Mortality  3  months Mortality  6  months Mortality  1  year
N  (%) p  Value N  (%) p  Value N  (%) p  Value N  (%) p  Value
COPD* 1.000 0.992 1.000 0.918
No 770  32  (4.1) 90  (11.7) 174  (22.6) 265  (34.4)
Yes 378 16  (4.2) 45  (11.9) 85  (22.5) 132  (34.9)
Cancer 0.860 0.096 0.002 <0.001
No 932  38  (4.1) 102  (10.9) 193  (20.7) 296  (31.8)
Yes 216 10  (4.6) 33  (15.3) 66  (30.6) 101  (46.8)
Anemia 0.951 0.150 0.006 <0.001
No 362  15  (4.1) 36  (9.9) 68  (18.8) 105  (29.0)
Yes 421 16  (3.8) 57  (13.5) 115  (27.3) 176  (41.8)
Hyponatremia 0.006 0.094 0.045 0.009
No 528  14  (2.6)  57  (10.0)  110  (20.8)  170  (32.2)
Yes 234  17  (7.2)  34  (14.5)  65  (27.8)  99  (42.3)
Total Mortality  1  month  Mortality  3  months  Mortality  6  months  Mortality  1  year
N  N  (%) p  Value N  (%) p  Value N  (%) p  Value N  (%) p  Value
Clinical  variables  (%)
Systolic  blood  pressure  0.070  0.072  0.001  0.006
>90 mmHg  1033  42  (4.07)  120  (11.6)  227  (22.0)  347  (33.6)
≤90 mmHg  37  4  (10.8)  8  (21.6)  17  (45.9)  21  (56.8)
Body mass  index  0.137  <0.001  <0.001  <0.001
≥20 kg/m2 819  28  (3.42)  74  (9.04)  149  (18.2)  244  (29.8)
<20 kg/m2 36  3  (8.33)  11  (30.6)  19  (52.8)  23  (63.9)
Heart rate  0.728  0.207  0.294  0.809
≤100 min--1 961  41  (4.27)  111  (11.6)  212  (22.1)  325  (33.8)
>100 min--1 55  3  (5.45)  10  (18.2)  16  (29.1)  20  (36.4)
Charlson 0.384  0.942  0.078  0.012
<6 993  39  (3.93)  116  (11.7)  215  (21.7)  329  (33.1)








Table  2  (Continued)
Total  Mortality  1  month  Mortality  3  months  Mortality  6  months  Mortality  1  year
N  N  (%)  p  Value  N  (%)  p  Value  N  (%)  p  Value  N  (%)  p  Value
Glomerular  filtration  1.000  0.032  0.001  <0.001
≥30 mL/min  719  29  (4.03)  76  (10.6)  150  (20.9)  233  (32.4)
<30 mL/min 97  3  (3.09)  18  (18.6)  36  (37.1)  52  (53.6)
Medication (%)
ACEi/ARB† 0.004  0.040  0.009  <0.001
No 390  26  (6.67)  57  (14.6)  106  (27.2)  162  (41.5)
Yes 758  22  (2.90)  78  (10.3)  153  (20.2)  235  (31.0)
Beta blockers  0.741  0.672  0.085  0.016
No 631  28  (4.44)  77  (12.2)  155  (24.6)  238  (37.7)
Yes 517  20  (3.87)  58  (11.2)  104  (20.1)  159  (30.8)
MRAs‡ 0.550  1.000  0.759  0.450
No 844  33  (3.91)  99  (11.7)  188  (22.3)  286  (33.9)
Yes 304  15  (4.93)  36  (11.8)  71  (23.4)  111  (36.5)
Doses of  loop  diuretics  (Mean,  SD§)  1148  57.9  (49.4)  0.763  60.0  (48.9)  0.287  61.7  (48.8)  0.025  60.8  (47.3)  0.008
Laboratory tests  (Mean,  SD)
Sodium  (mg/dL)  1148  140  (4.12)  0.094  140  (4.13)  0.512  141  (4.08)  0.361  140  (3.99)  0.143
Potassium (mg/dL)  1148  4.53  (0.59)  0.982  4.48  (0.63)  0.466  4.54  (0.62)  0.799  4.56  (0.59)  0.304
Creatinine (mg/dL)  1148  1.25  (0.58)  0.932  1.39  (0.69)  0.026  1.36  (0.73)  0.007  1.34  (0.65)  0.001
Hemoglobin (g/dL)  1148  12.1  (2.02)  0.869  11.8  (1.91)  0.083  11.8  (1.90)  0.003  11.9  (1.89)  0.001
* Chronic Obstructive Pulmonary Disease.
† ACEi/ARB indicates angiotensin converting enzyme inhibitor/Angiotensin II receptor blockers.
‡ MRAs, Mineralocorticoid Receptor Antagonists.
§ Standard deviation.




















Figure  2  Evolution  of  the  impact  of  factors  related  to  morta
Association.
In  relation  to  the  patients’  weight,  in  our  study,  the  risk
of  dying  for  patients  with  a  body  mass  index  <20  kg/m2 was
more  than  three  times  higher  than  in  the  rest.  Considerable
research  has  been  devoted  to  the  role  body  mass  index  plays
in  HF  patients.24 It  has  been  hypothesized  that  individuals
with  chronic  HF  and  obesity  have  significantly  lower  sym-
pathetic  activation.  This  may  partially  explain  the  obesity
paradox  described  in  chronic  HF  patients.25 The  higher  mor-
tality  related  to  low  body  mass  index  has  been  associated
with  higher  Tumoral  Necrosis  Factor-alfa,  adiponectin,  tro-
ponin  T  and  pulmonary  arterial  systolic  pressure.26 Whilst
we  could  not  measure  either  cachexia  or  sarcopenia  in
our  cohort  we  did  make  an  approximation  of  the  obesity
effect  by  measuring  body  mass  index.  It  has  been  shown
to  accurately  correlate  with  the  thickness  of  the  subcuta-
neous  fat  layer  and  is  accepted  as  a  measure  of  obesity
in  HF.27
Most  HF  prognostic  scores  consider  glomerular  filtration
as  an  independent  factor  of  death.  We  found  an  almost
two-fold  odds  ratio  of  mortality  in  patients  presenting  a
glomerular  filtration  <30  mL/min.  When  attempts  to  alle-
viate  congestion  are  limited  by  impaired  renal  function
the  cardiorenal  syndrome  appears.28 It  consists  of  a neuro
hormonal  adaptation  leading  to  renal-reduced  perfusion
and  right  ventricular  dysfunction.  Its  prevalence  is  around
60%  in  patients  with  acute  decompensation  and  up  to  51%






 patients  with  heart  failure  at  stage  IV  of  the  New  York  Heart
Although  it  may  appear  obvious  that  HF  patients  requiring
igher  loop  diuretic  doses  might  be  more  unwell  than  those
eceiving  lower  ones,  the  powerful  and  independent  asso-
iation  with  mortality  warrants  further  consideration.  Loop
iuretic  activation  of  the  renin-angiotensin-aldosterone  and
ympathetic  nervous  systems  has  been  shown  to  play  a  major
ole  in  the  pathophysiology  of  HF  and  may  be  associated  with
F  progression.30
The  protective  effect  on  early  mortality  of  ACEi/ARB  dis-
ppeared  along  the  follow  up.  We  cannot  ascertain  why  this
ffect  is  not  maintained,  but  probably  may  be  due  to  the
act  of  the  advanced  stage  of  the  disease,  where  could  be
ard  to  lengthen  the  survival  with  any  intervention.
An  association  between  anemia  and  increased  all-
ause  and  short-term  cardiovascular  mortality  has  been
eported.31 In  our  study,  the  trend  regarding  anemia  was
oward  a  higher  risk  although  it  was  not  statistically  signifi-
ant  at  multivariate  analysis.
trengths  and  limitations
ur  main  limitation  is  the  retrospective  design  and  the  fact
hat  data  were  gathered  from  electronic  medical  records.
evertheless,  SIDIAP  has  already  proven  to  be  a  valid  source
or  cardiovascular  disease  research.10 Some  variables  pre-
ented  missing  values  which  were  imputed  in  order  to  avoid


































nalysis.  A  strength  is  the  large  cohort  of  patients  with  sta-
le,  advanced  HF  managed  in  the  community.
It  would  be  necessary  further  studies  to  properly  explain
ome  of  the  findings,  such  as  the  role  of  ACEi/ARB  on  the
urvival  of  patients  at  advances  stages  of  HF.
Nevertheless  the  initial  objective  of  our  study  was  not  to
est  the  efficacy  of  treatments  in  enlarging  the  survival  but
o  identify  factors  related  with  a  poorer  prognosis  in  order
o  be  able  to  discuss  with  the  patients  and  their  families  the
est  way  to  face  the  end  of  life.
onclusions
mong  stable,  ambulatory  HF  patients,  male  gender,  age,
nd  low  body  mass  index  are  involved  in  higher  mortality
t  both  short  and  long-term  after  reaching  NYHA  IV  stages.
n  addition,  low  SBP,  reduced  glomerular  filtration,  malig-
ancy,  and  higher  necessity  in  the  doses  of  loop  diuretics
ontribute  to  increasing  the  risk  of  mortality  at  medium  and
ong-term.  Such  variables  are  easily  measurable  in  primary
are  and  may  help  health  professionals  identify  HF  patients
ith  worse  outcomes  and  decide  with  patients  and  their
amilies  the  best  way  to  face  the  most  advanced  stages  of
he  disease.
Key Points
What  is  known  about  the  subject/What  does  this
study contribute
1.  Clinical  course  of  HF  is  progressive  and,  in  advanced
stages  leads  to  a  number  of  hospitalizations,  trans-
plantation  or  death.
2.  Palliative  measures  can  help  to  better  manage
patients  at  final  stages.
3.  Since  the  uncertainty  of  the  evolution  at  final  stages
it  is  difficult  to  ascertain  which  patients  could  ben-
efit  from  homecare  and  palliative  measures.
4.  To  know  the  factors  related  to  a  worse  short  term
prognostic  may  help  to  take  decisions  about  their
care.
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